BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21231897)

  • 1. Pharmacoeconomic evaluation of warfarin pharmacogenomics.
    You JH
    Expert Opin Pharmacother; 2011 Feb; 12(3):435-41. PubMed ID: 21231897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation.
    Verhoef TI; Redekop WK; Veenstra DL; Thariani R; Beltman PA; van Schie RM; de Boer A; Maitland-van der Zee AH;
    Pharmacogenomics; 2013 Jun; 14(8):869-83. PubMed ID: 23746182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.
    Leey JA; McCabe S; Koch JA; Miles TP
    Am J Geriatr Pharmacother; 2009 Aug; 7(4):197-203. PubMed ID: 19766951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.
    Martes-Martinez C; Méndez-Sepúlveda C; Millán-Molina J; French-Kim M; Marín-Centeno H; Rivera-Miranda GC; Hernández-Muñoz JJ; Duconge-Soler J
    P R Health Sci J; 2017 Sep; 36(3):165-172. PubMed ID: 28915306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand.
    Chong HY; Saokaew S; Dumrongprat K; Permsuwan U; Wu DB; Sritara P; Chaiyakunapruk N
    Thromb Res; 2014 Dec; 134(6):1278-84. PubMed ID: 25456732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.
    You JH; Chan FW; Wong RS; Cheng G
    Thromb Haemost; 2004 Sep; 92(3):590-7. PubMed ID: 15351856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics and warfarin therapy.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Oct; (104):1-8. PubMed ID: 17912794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
    Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-guided warfarin therapy: current status.
    Tavares LC; Marcatto LR; Santos PCJL
    Pharmacogenomics; 2018 May; 19(7):667-685. PubMed ID: 29701078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
    Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
    Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical applications of pharmacogenomics guided warfarin dosing.
    Mahajan P; Meyer KS; Wall GC; Price HJ
    Int J Clin Pharm; 2011 Feb; 33(1):10-9. PubMed ID: 21365388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.
    Meckley LM; Gudgeon JM; Anderson JL; Williams MS; Veenstra DL
    Pharmacoeconomics; 2010; 28(1):61-74. PubMed ID: 20014877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event.
    Aujesky D; Smith KJ; Roberts MS
    Am J Med; 2005 Jun; 118(6):625-35. PubMed ID: 15922694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomic-guided dosing for warfarin: too little too late?
    Wu AH
    Per Med; 2018 Mar; 15(2):71-73. PubMed ID: 29714120
    [No Abstract]   [Full Text] [Related]  

  • 16. Warfarin pharmacogenomics: a big step forward for individualized medicine: enlightened dosing of warfarin.
    Elias DJ; Topol EJ
    Eur J Hum Genet; 2008 May; 16(5):532-4. PubMed ID: 18301451
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
    Davidson T; Husberg M; Janzon M; Oldgren J; Levin LÅ
    Eur Heart J; 2013 Jan; 34(3):177-83. PubMed ID: 22733833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
    Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM
    Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical applications of pharmacogenomics guided warfarin dosing.
    Mahajan P; Meyer KS; Wall GC; Price HJ
    Int J Clin Pharm; 2013 Jun; 35(3):359-68. PubMed ID: 21052837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics and the management of oral anticoagulation.
    Wittkowsky AK
    Curr Hematol Rep; 2004 Sep; 3(5):363-7. PubMed ID: 15341704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.